267 related articles for article (PubMed ID: 22561315)
1. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
2. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
4. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
6. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
9. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
12. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
13. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications.
Acedo L; Díez-Domingo J; Moraño JA; Villanueva RJ
Epidemiol Infect; 2010 Jun; 138(6):853-60. PubMed ID: 20003640
[TBL] [Abstract][Full Text] [Related]
16. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
